NewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 1-Year High – Time to Buy?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) reached a new 52-week high on Monday . The stock traded as high as $42.21 and last traded at $41.59, with a volume of 528706 shares. The stock had previously closed at $38.73.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Truist Financial assumed coverage on shares of NewAmsterdam Pharma in a report on Wednesday, March 18th. They set a “buy” rating and a $57.00 price objective for the company. Needham & Company LLC raised their price objective on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Royal Bank Of Canada raised their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Finally, Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and an average target price of $48.00.

NewAmsterdam Pharma Stock Performance

The firm’s 50-day moving average is $31.77 and its two-hundred day moving average is $34.24. The stock has a market cap of $4.55 billion, a P/E ratio of -22.12 and a beta of 0.02.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) earnings per share for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million during the quarter. As a group, research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.81 EPS for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CEO Michael H. Davidson sold 443,707 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $33.25, for a total value of $14,753,257.75. Following the transaction, the chief executive officer directly owned 174,144 shares of the company’s stock, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 104,467 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $30.30, for a total transaction of $3,165,350.10. Following the completion of the transaction, the insider directly owned 69,302 shares in the company, valued at approximately $2,099,850.60. The trade was a 60.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 1,168,286 shares of company stock valued at $38,211,967. 12.74% of the stock is currently owned by insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its stake in NewAmsterdam Pharma by 50.0% in the fourth quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after acquiring an additional 300 shares during the last quarter. Geode Capital Management LLC boosted its stake in NewAmsterdam Pharma by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock valued at $3,590,000 after acquiring an additional 437 shares during the last quarter. Arizona State Retirement System boosted its stake in NewAmsterdam Pharma by 3.8% in the third quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $377,000 after acquiring an additional 483 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in NewAmsterdam Pharma by 5.3% in the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after acquiring an additional 544 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after acquiring an additional 708 shares during the last quarter. 89.89% of the stock is owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.